Forecast Of The Day: Medtronic Surgical Innovations Revenue

+25.82%
Upside
90.49
Market
114
Trefis
MDT: Medtronic logo
MDT
Medtronic

What?

Trefis expects Medtronic’s (NYSE:MDT) Surgical Innovations revenue – which includes surgical stapling devices, vessel sealing instruments, wound closure, and related products – to remain roughly flat at around $5.5 billion between 2020 and 2021 and rise to around $5.9 billion in 2022.

Why?

Relevant Articles
  1. Will Medtronic Stock See Higher Levels?
  2. Will Medtronic Stock See Higher Levels Following Its Q4 Results?
  3. Here’s What Makes Medtronic Stock A Better Pick Over This Pharmaceuticals Company
  4. Is There A Better Pick Over Medtronic Stock?
  5. This Medical Devices Company Is Likely To Offer Better Returns Over Medtronic Stock
  6. Company Of The Day: Medtronic

While the spread of Covid-19 has reduced doctors visits and elective surgical procedures impacting sales of surgical products, we expect revenue to recover from next year.

So What?

MDT stock has underperformed year-to-date, rising by just about 10%, compared to the S&P 500 which is up 17%. However, we think the stock is undervalued, with our price estimate standing at $148 per share, about 15% ahead of the current market price.

See Our Complete Analysis For Medtronic

 

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016

See all Trefis Price Estimates and Download Trefis Data here

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams